Inactive Instrument

Synthorx, Inc.

Equities

US87167A1034

Synthorx, Inc.(NasdaqGM:THOR) dropped from S&P TMI Index

January 24, 2020 at 12:00 am EST

Latest news about Synthorx, Inc.

Synthorx, Inc.(NasdaqGS:THOR) dropped from S&P Global BMI Index	20-01-24	CI
Synthorx, Inc.(NasdaqGM:THOR) dropped from S&P TMI Index	20-01-24	CI
Synthorx, Inc. Announces Executive Changes	20-01-23	CI
Synthorx, Inc.(NasdaqGS:THOR) dropped from NASDAQ Composite Index	20-01-23	CI
Sanofi completed the acquisition of Synthorx, Inc. from Avalon Ventures, LLC, Correlation Ventures, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and others.	20-01-22	CI
Tesla gets Chinese boost, Boeing’s new troubles, scandal for Tesco…	19-12-23
Synthorx : Sanofi shares rally on new margin goals, narrower drug focus	19-12-10	RE
Synthorx : Sanofi ends research in diabetes, narrows units to spur profit	19-12-09	RE
European shares dragged down by Tullow Oil and weak China export data	19-12-09	RE
Synthorx : France's Sanofi to buy biotech firm Synthorx for $2.5 billion	19-12-09	RE
Synthorx : France's Sanofi to buy biotech firm Synthorx for $2.5 billion	19-12-09	RE
Sanofi entered into definitive agreement to acquire Synthorx, Inc. from Avalon Ventures, LLC, Correlation Ventures, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and others for $2.2 billion.	19-12-08	CI
Synthorx, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-05	CI
Synthorx, Inc. to Present THOR-809 Data at the American College of Rheumatology Annual Meeting	19-11-05	CI
Synthorx to Present At the European Society for Medical Oncology 2019 Congress	19-09-23	CI
Synthorx, Inc. Announces Resignation of Floyd Romesberg from the Board of Directors	19-09-13	CI
Synthorx, Inc. Enters into a Sub-Sublease with Avelas Biosciences, Inc	19-09-04	CI
Synthorx, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-01	CI
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of Investigational New Drug in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707	19-07-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Synthorx, Inc.(NasdaqGS:THOR) added to S&P Global BMI Index	19-06-24	CI
Certain Common Stock of Synthorx, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2019.	19-06-04	CI
Certain Stock Options of Synthorx, Inc. are subject to a Lock-Up Agreement Ending on 5-JUN-2019.	19-06-04	CI
Synthorx, Inc. to Present Preclinical Data Demonstrating the Potential Safety and Anti-Tumor Effects of its Lead Product Candidate, THOR-707 at the 2019 American Society of Clinical Oncology Annual Meeting	19-05-15	CI

Chart Synthorx, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company